A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 27 Apr 2016 Status changed from recruiting to completed.
- 05 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 05 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.